A novel nonribose agonist, LUF5834, engages residues that are distinct from those of adenosine-like ligands to activate the adenosine A 2a receptor

Molecular Pharmacology

Volumn 81, Issue 3, 2012, Pages 475-487

  Lane, J Robert ^a,c   Herenbrink, Carmen Klein ^a   Van Westen, Gerard J P ^a   Spoorendonk, Jelle A ^a   Hoffmann, Carsten ^a,b,c   IJzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 AMINO 4 (4 HYDROXYPHENYL) 6 (1H IMIDAZOL 2 YLMETHYLSULFANYL)PYRIDINE 3,5 DICARBONITRILE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ALANINE; CYANOPINDOLOL; GLUTAMINE; LIGAND; LUF 5834; PHENYLALANINE; PYRIDINE DERIVATIVE; RIBOSE; TRYPTOPHAN; UK 432097; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; STEREOSPECIFICITY;

AMINOPYRIDINES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMIDAZOLES; LIGANDS; MUTAGENESIS; RECEPTOR, ADENOSINE A2A;

EID: 84857418044     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.075937     Document Type: Article

References (42)

1. Beukers MW, Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, and IJzerman AP (2004) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N- ethylcarboxamidoadenosine. J Med Chem 47:3707-3709. (Pubitemid 38900337)
2. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162. (Pubitemid 14217337)
3. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463:108-112.
4. Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, and IJzerman AP (2005) A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 48:2045-2053. (Pubitemid 40396332)
5. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
6. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374. (Pubitemid 34575719)
7. Cooper J, Hill SJ, and Alexander SP (1997) An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells. Br J Pharmacol 122:546-550. (Pubitemid 27429731)
8. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, and Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
9. Gao ZG, Jiang Q, Jacobson KA, and IJzerman AP (2000) Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol 60:661-668. (Pubitemid 30604248)
10. 1B receptor on CHO cells: functional responses in the absence of radioligand binding. Br J Pharmacol 117:1119-1126.
11. Heitman LH, Mulder-Krieger T, Spanjersberg RF, von Frijtag Drabbe Künzel JK, Dalpiaz A, and IJzerman AP (2006) Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol 147:533-541. (Pubitemid 43355051)
12. Hoffmann C, Gaietta G, Bünemann M, Adams SR, Oberdorff-Maass S, Behr B, Vilardaga JP, Tsien RY, Ellisman MH, and Lohse MJ (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods 2:171-176. (Pubitemid 41122123)
13. Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, Frimurer TM, and Schwartz TW (2010) A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J Biol Chem 285:3973-3985.
14. IJzerman AP, Von Frijtag Drabbe Künzel JK, Kim J, Jiang Q, and Jacobson KA (1996) Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. Eur J Pharmacol 310:269-272. (Pubitemid 26298271)
15. Ivanov AA, Barak D, and Jacobson KA (2009) Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem 52:3284-3292.
16. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, IJzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
17. Jaakola VP, Lane JR, Lin JY, Katritch V, IJzerman AP, and Stevens RC (2010) Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. J Biol Chem 285:13032-13044.
18. Jacobson KA and Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264. (Pubitemid 43336037)
19. Jacobson KA, Ohno M, Duong HT, Kim SK, Tchilibon S, Cesnek M, Holý A, and Gao ZG (2005) A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. Chem Biol 12:237-247. (Pubitemid 40281331)
20. Jiang Q, Van Rhee AM, Kim J, Yehle S, Wess J, and Jacobson KA (1996) Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol 50:512-521. (Pubitemid 26303581)
21. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
22. Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, and Jacobson KA (1996) Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol 49:683-691.
23. 2Aadenosine receptor. J Biol Chem 270:13987-13997.
24. Kim SK, Gao ZG, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, and Jacobson KA (2003) Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem 46:4847-4859. (Pubitemid 37352025)
25. Kobilka BK (2011) Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci 32:213-218.
26. 3H]LUF5834: a novel non-ribose high-affinity agonist radio-ligand for the adenosine A1 receptor. Biochem Pharmacol 80:1180-1189.
27. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, and Tate CG (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521-525.
28. Miyamoto MI, Clarke KA, Thomas GS, and Belardinelli L (2009) An example of the clinical selectivity of regadenoson for the A2a adenosine receptor. Am Heart Hosp J 7:E118-E121.
29. Peeters MC, van Westen GJ, Guo D, Wisse LE, Müller CE, Beukers MW, and IJzerman AP (2011) GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J 25:632-643.
30. Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M, Dumuis A, Claeysen S, Bockaert J, and Pardo L (2009) Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine- 4 receptors. Mol Pharmacol 75:982-990.
31. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, et al. (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature 469:175-180.
32. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, et al. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469:236-240.
33. Rosentreter U, Henning R, Bauser M, Kraemer T, Vaupel A, Huebsch W, Dembowsky K, Salcher-Schraufstaetter O, Stasch J, Krahn T, et al. (2001), inventors; Bayer Aktiengesellschaft, Rosentreter U, Henning R, Bauser M, Kraemer T, Vaupel A, Huebsch W, Dembowsky K, Salcher-Schraufstaetter O, Stasch J, Krahn T, et al., assignees. Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands. World patent WO01025210. 2001 Apr 12.
34. Rosentreter U, Kraemer T, Shimada M, Huebsch W, Diedrichs N, Krahn T, Henninger K, and Stasch J (2003), inventors; Bayer Aktiengesellschaft, Rosentreter U, Kraemer T, Shimada M, Huebsch W, Diedrichs N, Krahn T, Henninger K, and Stasch J, assignees. Preparation of 2-heteroarylmethyltio-3,5-dicyano-4- phenyl-6- aminopyridines as adenosine receptor selective ligands. World patent WO03008384. 2003 Jan 30.
35. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455:497-502.
36. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 277:40989-40996. (Pubitemid 35215688)
37. Soudijn W, van Wijngaarden I, and IJzerman AP (2003) Medicinal chemistry of adenosine A1 receptor ligands. Curr Top Med Chem 3:355-367.
38. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171. (Pubitemid 40827872)
39. Tschammer N, Bollinger S, Kenakin T, and Gmeiner P (2011) Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 79:575-585.
40. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, and Tate CG (2011) The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor. Nature 469:241-244.
41. Wieland K, Zuurmond HM, Krasel C, IJzerman AP, and Lohse MJ (1996) Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci USA 93:9276-9281. (Pubitemid 26282054)
42. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, and Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322-327.